Zemelka-Wiacek Magdalena
Department of Clinical Immunology, Faculty of Medicine, Wroclaw Medical University, 50-367 Wrocław, Poland.
J Clin Med. 2024 Nov 29;13(23):7268. doi: 10.3390/jcm13237268.
Allergic diseases triggered by airborne allergens such as allergic rhinitis and conjunctivitis are increasingly prevalent, posing significant challenges for both patients and healthcare systems. Assessing the efficacy of allergen immunotherapy and other anti-allergic treatments requires precise and reproducible methods. Allergen exposure chambers (AECs) have emerged as advanced tools for evaluating clinical outcomes, offering controlled conditions that address many limitations of traditional field-based studies. This review explores the advantages of AECs in allergy management, emphasizing their role in providing standardized allergen exposure for both clinical research and routine assessments. AECs deliver consistent and reproducible data comparable to the nasal allergen challenge and natural allergen exposure, making them a valuable addition to the diagnosis and treatment effectiveness of allergic diseases. Although they are well suited to early-stage clinical trials, further standardization and validation are needed to gain broader acceptance in pivotal phase III studies. Future research should focus on refining AEC protocols and integrating them into regulatory frameworks, ensuring their role in the advancement of therapeutic approaches for allergic diseases.
由空气传播过敏原引发的过敏性疾病,如过敏性鼻炎和结膜炎,正日益普遍,给患者和医疗系统都带来了重大挑战。评估变应原免疫疗法和其他抗过敏治疗的疗效需要精确且可重复的方法。变应原暴露舱(AECs)已成为评估临床结果的先进工具,提供了可控条件,解决了传统现场研究的许多局限性。本综述探讨了AECs在过敏管理中的优势,强调了它们在为临床研究和常规评估提供标准化变应原暴露方面的作用。AECs提供的数据一致且可重复,可与鼻内变应原激发试验和自然变应原暴露相媲美,使其成为过敏性疾病诊断和治疗效果评估的宝贵补充。尽管它们非常适合早期临床试验,但需要进一步标准化和验证,以在关键的III期研究中获得更广泛的认可。未来的研究应专注于完善AEC方案并将其纳入监管框架,确保它们在推进过敏性疾病治疗方法方面的作用。